Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CellSeedTSE:7776 +1.79%51 3-1 Month Momentum % is 1.79% as of Sep. 09, 2026. GuruFocus rates TSE:7776 with a GF Score™ of 51/100 and a GF Value™ of 円151.88 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,386 Biotechnology companies, CellSeed ranks better than 51.23% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-09), CellSeed's 3-1 Month Momentum % is 1.79%.
The industry rank for CellSeed's 3-1 Month Momentum % or its related term are showing as below:
TSE:7776's 3-1 Month Momentum % is ranked better than 51.23% of 1386
companies
in the Biotechnology industry
Industry Median: 1.085
vs TSE:7776: 1.79
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
CellSeed 3-1 Month Momentum % Related Terms
TSE:7776 vs VRTX, REGN, MRNA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, CellSeed's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSeed 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSeed's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where CellSeed's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellSeed (TSE:7776) has a 3-1 Month Momentum % of 1.79% as of Sep. 09, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on CellSeed and its competitors. According to the industry distribution chart, CellSeed ranks #676 out of 1386 companies in the Biotechnology industry, placing it in the top 48.8%.
Is CellSeed's 3-1 Month Momentum % too high?
CellSeed's current 3-1 Month Momentum % is 1.79%. The Biotechnology industry median 3-1 Month Momentum % is 1.09. CellSeed's value of 1.79% is 65% above this industry median. Based on the distribution chart, CellSeed ranks #676 out of 1386 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CellSeed has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CellSeed's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CellSeed ranks #676 out of 1386 companies for 3-1 Month Momentum %. This puts CellSeed in the upper half of its industry. The industry median 3-1 Month Momentum % is 1.09. CellSeed's value of 1.79% is 65% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 1.09, based on 1,386 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellSeed's current 3-1 Month Momentum % of 1.79% is 65% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on CellSeed and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 1.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellSeed's current 3-1 Month Momentum % is 1.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSeed stock overvalued right now?
Based on GuruFocus' analysis, CellSeed (TSE:7776) is currently considered Significantly Overvalued. The stock's GF Value™ is 円151.88, compared to a current price of 円227.00 — trading 49.5% above its estimated fair value. The current 3-1 Month Momentum % is 1.79% and 65% above the Biotechnology industry median of 1.09. CellSeed's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For CellSeed (TSE:7776), the current 3-1 Month Momentum % is 1.79% as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSeed (TSE:7776) Overvalued in 2026?
Based on GuruFocus' analysis, CellSeed stock appears to be overvalued.
The current stock price of 円227.00 is trading 49.5% above its estimated GF Value™ of 円151.88.
GuruFocus considers CellSeed to be Significantly Overvalued.
Key valuation signals for TSE:7776:
3-1 Month Momentum %: 1.79%
GF Value™: 円151.88 vs. price of 円227.00 (49.5% above fair value)
Industry Position: 65% above the Biotechnology median (#676 of 1386)
No single metric tells the full story. See the TSE:7776 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSeed Inc is a Japanese biotechnology company. The company is involved in the research, development, marketing, and sale of cell-sheet regenerative medicines, such as epithelial cell sheets for corneal and esophageal regeneration; regenerated cardiac patches to treat heart diseases; cell sheets for periodontal tissue regeneration; and regenerated cartilage sheets for the treatment of osteoarthritis.
51GF Score
Get the complete analysis for TSE:7776
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7776 has been successfully added to your 
